Sunday, October 18, 2020 3:17:20 PM
If understand correctly, Revive must have repurposed Rimatil (Bucillamine),
If the clinical trial phase III of Bucillamine is successful, Chong Kun Dang (Santen Company), which has exclusive domestic sales rights, will obtain COVID-19 treatment indication. Guess, in EAST ASIA only.
If the clinical trial phase III of Bucillamine is successful, Chong Kun Dang (Santen Company), which has exclusive domestic sales rights, will obtain COVID-19 treatment indication. Guess, in EAST ASIA only.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
